3 completed, 3 unknown, 1 active not recruiting, 1 not yet recruiting. 10 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 10 | Completed 3, Unknown 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow Neuromyelitis Optica: new trials by email Literature Review of Neuromyelitis Optica trials Research Report on Neuromyelitis Optica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial Crisugabalin, Placebo+Crisugabalin - Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain | Phase 4 | Not yet recruiting | Tang-Du Hospital | 110 | 2026-06-15 | 2026-07-13 |
| Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study Eculizumab+IVMP, IVIG+IVMP, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 4 | Recruiting | Chinese PLA General Hospital | 200 | 2026-02-01 | 2026-03-12 |
| Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Blood tests, Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Active not recruiting | Amgen | 32 | 2024-04-02 | 2025-11-21 |
| A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Inebilizumab - Neuromyelitis Optica Spectrum Disorders | Phase 4 | Unknown | Hansoh BioMedical R&D Company | 33 | 2024-02-25 | 2024-01-18 |
| A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention Satralizumab 120 mg - Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 4 | Terminated | Hoffmann-La Roche | 4 | 2022-08-02 | 2025-01-22 |
| Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder Azathioprine - NMO Spectrum Disorder, Azathioprine Adverse Reaction | Phase 4 | Completed | First Affiliated Hospital of Guangxi Medical University | 63 | 2020-01-01 | 2023-06-09 |
| Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Mycophenolate mofetil, Prednisone - Neuromyelitis Optica Spectrum Disorders, Mycophenolate Mofetil | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 100 | 2016-01-01 | 2016-06-22 |
| Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) Rituximab - Neuromyelitis Optica Spectrum Disorder | Phase 4 | Completed | Tang-Du Hospital | 108 | 2014-04-01 | 2020-10-19 |
| Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Mitoxantrone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorders | Phase 4 | Unknown | Xuanwu Hospital, Beijing | 50 | 2009-03-01 | 2013-12-27 |
| A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) Mitoxantrone - Neuromyelitis Optica, Myelitis, Transverse | Phase 4 | Completed | State University of New York at Buffalo | 5 | 2001-08-01 | 2020-12-28 |
Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Myelitis, Transverse (1) · Neuralgia (1) · Recurrence (1)
Autoimmune Diseases (10) · Cranial Nerve Diseases (10) · Demyelinating Diseases (10) · Eye Diseases (10) · Immune System Diseases (10) · Nervous System Diseases (10) · Optic Nerve Diseases (10) · Optic Neuritis (10) · Autoimmune Diseases of the Nervous System (9) · Demyelinating Autoimmune Diseases, CNS (9) · Myelitis, Transverse (9) · Pathological Conditions, Signs and Symptoms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1)
Mitoxantrone (2) · inebilizumab (2) · Azathioprine (1) · Hematologic Tests (1) · Mycophenolic Acid (1) · Prednisone (1) · Rituximab (1) · satralizumab (1)
Tang-Du Hospital (2) · Amgen (1) · Chinese PLA General Hospital (1) · First Affiliated Hospital of Guangxi Medical University (1) · Hansoh BioMedical R&D Company (1) · Hoffmann-La Roche (1) · State University of New York at Buffalo (1) · Third Affiliated Hospital, Sun Yat-Sen University (1) · Xuanwu Hospital, Beijing (1)
China (6) · United States (3) · South Korea (2) · Czechia (1) · Hungary (1) · Poland (1) · Thailand (1) · Turkey (Türkiye) (1)
Bianca Weinstock-Guttman, M.D. (1) · Hongzeng Li (1) · Huiqing Dong, Doctor (1) · Jun Guo (1) · Wei Qiu, Medical PhD (1) · Yulan Tang (1)
PMID 16638802, PMID 16831964, PMID 19752302, PMID 25199960, PMID 30258442